Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (33) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (6) Apply Summaries of opinion filter Withdrawn applications (29) Apply Withdrawn applications filter Orphan designations (70) Apply Orphan designations filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (348) Apply Authorised filter Refused (1) Apply Refused filter Withdrawn (70) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (6) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (57) Apply PM: decision on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (13) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (16) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (7) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (3) Apply Yes filter

Referral type

Article 20 procedures (4) Apply Article 20 procedures filter Article 31 referrals (4) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (5) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (4) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (4) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Generic Remove Generic filter Additional monitoring (610) Apply Additional monitoring filter Biosimilar (94) Apply Biosimilar filter Orphan medicine (261) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

521 results

Remove all filtersRemove all filters

Categories Human Remove Human filter

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Paediatric investigation plans Remove Paediatric investigation plans filter

Medicine type Generic Remove Generic filter Accelerated assessment Remove Accelerated assessment filter Exceptional circumstances Remove Exceptional circumstances filter Conditional approval Remove Conditional approval filter

Sort by

List item

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)

Chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous; Metabolism, Inborn Errors
Date of authorisation: 10/04/2017, , , , Revision: 5, Authorised, Last updated: 15/12/2021
List item

Human medicine European public assessment report (EPAR): Ciambra

pemetrexed disodium hemipentahydrate, Carcinoma, Non-Small-Cell Lung; Mesothelioma
Date of authorisation: 02/12/2015, , Revision: 6, Authorised, Last updated: 17/08/2022
List item

Human medicine European public assessment report (EPAR): Cinacalcet Accordpharma

cinacalcet hydrochloride, Hyperparathyroidism
Date of authorisation: 03/04/2020, , Revision: 2, Authorised, Last updated: 26/01/2022
List item

Human medicine European public assessment report (EPAR): Cinacalcet Mylan

cinacalcet hydrochloride, Hyperparathyroidism, Secondary; Hypercalcemia
Date of authorisation: 19/11/2015, , Revision: 14, Authorised, Last updated: 12/09/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan

acetylsalicylic acid, clopidogrel hydrogen sulfate, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 09/01/2020, , Revision: 4, Authorised, Last updated: 02/08/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel 1A Pharma

clopidogrel, Peripheral Vascular Diseases
Date of authorisation: 28/07/2009, , Revision: 1, Withdrawn, Last updated: 28/02/2011
List item

Human medicine European public assessment report (EPAR): Clopidogrel Acino

clopidogrel, Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/07/2009, , Revision: 6, Withdrawn, Last updated: 04/01/2018
List item

Human medicine European public assessment report (EPAR): Clopidogrel Acino Pharma

clopidogrel, Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/09/2009, , Revision: 1, Withdrawn, Last updated: 26/07/2012
List item

Human medicine European public assessment report (EPAR): Clopidogrel Acino Pharma GmbH

clopidogrel, Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/09/2009, , Revision: 1, Withdrawn, Last updated: 26/07/2012
List item

Human medicine European public assessment report (EPAR): Clopidogrel BGR (previously Zylagren)

clopidogrel (as hydrogen sulfate), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/09/2009, , Revision: 17, Authorised, Last updated: 11/03/2020
List item

Human medicine European public assessment report (EPAR): Clopidogrel DURA

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/07/2009, , Revision: 6, Withdrawn, Last updated: 10/07/2015
List item

Human medicine European public assessment report (EPAR): Clopidogrel HCS

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/10/2010, , Revision: 8, Authorised, Last updated: 01/08/2018
List item

Human medicine European public assessment report (EPAR): Clopidogrel Hexal

clopidogrel, Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/07/2009, , Revision: 2, Withdrawn, Last updated: 26/07/2012
List item

Human medicine European public assessment report (EPAR): Clopidogrel Krka

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 23/09/2009, , Revision: 18, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Krka d.d. (previously Zopya)

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 20/09/2009, , Revision: 14, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Qualimed

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 23/09/2009, , Revision: 4, Withdrawn, Last updated: 08/09/2014
List item

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm

clopidogrel, Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 23/09/2009, , Revision: 5, Withdrawn, Last updated: 12/12/2013
List item

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm

clopidogrel (as hydrogen sulfate), Myocardial Infarction; Acute Coronary Syndrome; Peripheral Vascular Diseases; Stroke
Date of authorisation: 18/02/2015, , Revision: 14, Authorised, Last updated: 15/11/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm GmbH

clopidogrel, Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/07/2009, , Revision: 12, Withdrawn, Last updated: 25/01/2021
List item

Human medicine European public assessment report (EPAR): Clopidogrel Sandoz

clopidogrel, Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/09/2009, , Revision: 2, Withdrawn, Last updated: 26/10/2011
List item

Human medicine European public assessment report (EPAR): Clopidogrel TAD

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 23/09/2009, , Revision: 15, Authorised, Last updated: 08/07/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan)

clopidogrel hydrochloride, Peripheral Vascular Diseases; Stroke; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 21/09/2009, , Revision: 20, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate)

clopidogrel (as hydrogen sulfate), Acute Coronary Syndrome; Peripheral Vascular Diseases; Myocardial Infarction; Stroke
Date of authorisation: 27/07/2009, , Revision: 18, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Clopidogrel Teva Generics B.V.

clopidogrel (as hydrochloride), Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
Date of authorisation: 28/10/2010, , Revision: 3, Withdrawn, Last updated: 12/05/2014
List item

Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma (previously Clopidogrel HCS)

clopidogrel (as hydrochloride), Myocardial Infarction; Peripheral Vascular Diseases; Stroke
Date of authorisation: 21/09/2009, , Revision: 9, Withdrawn, Last updated: 24/10/2017

Load more

521 results

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)

Human medicine European public assessment report (EPAR): Ciambra

Human medicine European public assessment report (EPAR): Cinacalcet Accordpharma

Human medicine European public assessment report (EPAR): Cinacalcet Mylan

Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan

Human medicine European public assessment report (EPAR): Clopidogrel 1A Pharma

Human medicine European public assessment report (EPAR): Clopidogrel Acino

Human medicine European public assessment report (EPAR): Clopidogrel Acino Pharma

Human medicine European public assessment report (EPAR): Clopidogrel Acino Pharma GmbH

Human medicine European public assessment report (EPAR): Clopidogrel BGR (previously Zylagren)

Human medicine European public assessment report (EPAR): Clopidogrel DURA

Human medicine European public assessment report (EPAR): Clopidogrel HCS

Human medicine European public assessment report (EPAR): Clopidogrel Hexal

Human medicine European public assessment report (EPAR): Clopidogrel Krka

Human medicine European public assessment report (EPAR): Clopidogrel Krka d.d. (previously Zopya)

Human medicine European public assessment report (EPAR): Clopidogrel Qualimed

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm

Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm GmbH

Human medicine European public assessment report (EPAR): Clopidogrel Sandoz

Human medicine European public assessment report (EPAR): Clopidogrel TAD

Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Mylan)

Human medicine European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate)

Human medicine European public assessment report (EPAR): Clopidogrel Teva Generics B.V.

Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma (previously Clopidogrel HCS)